Recurrent Localized Pseudomyxoma Peritonei in the Female Pelvis

Igor Mishin a  Gheorghe Ghidirim a  Eugen Gladun b  Anna Mishina b  Marin Vozian a

a First Department of Surgery ‘N. Anestiadi’ and Laboratory of Hepato-Pancreato-Biliary Surgery, National Center of Emergency Medicine, b Department of Surgical Gynecology, Medical University ‘N. Testemitsanu’, Kishinev, Moldova

Keywords
Pseudomyxoma · Recurrence · Localization · Pelvis

Summary
Objective: Pseudomyxoma peritonei (PMP) is a rare, chronic, relapsing, diagnostically challenging, and poorly understood disease characterized by disseminated mucinous ascites and peritoneal implants. PMP usually develops secondary to mucinous neoplasms of the appendix and/or the ovary. Only few reports of limited PMP were published. Case Report: We describe the case of a 53-year-old woman who presented with a limited mucinous collection in the pelvis seen on computed tomography and who underwent surgery for mucocele of the appendix, bilateral mucinous ovarian tumors, and single mucinous implant on the great omentum 16 years previously. Serum tumor markers: CEA was elevated and CA 19-9 was within the normal range. At surgery, a well-circumscribed collection of mucin was found in the pelvis, and removal of mucinous material with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and postoperative intraperitoneal irrigation with 5-fluorouracil was performed. Histological examination revealed disseminated peritoneal adenomucinosis according to Ronnett’s classification. After surgery, the patient has been free of recurrence for 2 years. Conclusion: Our case report highlights that PMP requires careful observation, as it might be detected after a long-term follow-up period post-appendectomy for appendiceal mucocele.

Schlüsselwörter
Pseudomyxom · Rezidiv · Lokalisation · Becken

Zusammenfassung
Introduction

Pseudomyxoma peritonei (PMP) is a rare neoplastic condition in which gelatinous intraperitoneal fluid collections associated with disseminated mucinous tumor implants are observed. Although ruptured appendiceal mucocele is the most common cause of this condition, pathologic findings arising from other origins such as the ovary, pancreas, intestine, bile duct, and urachus may also cause PMP [1]. When mucinous fluid-like materials localize in the female pelvic cavity, which is an infrequent condition, this may mimic ovarian carcinomatous peritonitis and may be treated as a gynecologic disease [2]. Only sporadic reports of limited PMP were published [2]. We hereby report an additional case of localized PMP in the female pelvis.

Case Report

A 53-year-old woman was referred to our hospital in order to evaluate a pelvic mass. She was complaining about pain in the lower abdomen and dysuria. Her past medical history was significant in terms of subtotal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and appendectomy for mucocele of the appendix, bilateral mucinous ovarian tumors, and single mucinous implant on the great omentum 16 years previously. The pathologic examination of the surgical specimen demonstrated appendiceal mucinous cystadenoma and bilateral ovarian mucinous cysts. 10 years later, she presented with pain in the lower abdomen and limited fluid collection in the pelvis; during surgery, a mucin-filled cavity was found in the pelvis and removal of the mucinous content was performed.

Admission routine tests were within the normal ranges, while tumor markers were either elevated (CEA: 10.4 ng/l; upper limit of normal range: 0.5 ng/l) or within normal range (CA 19-9: 23.9 U/ml; upper limit of normal range: 37 U/ml). Computed tomography (CT) revealed a 120 × 83 mm oval-shaped encapsulated fluid collection in the pelvis between rectum and bladder with calcification in the wall (fig. 1a,b). The CT findings were confirmed during surgery. An encapsulated mass in the pelvic cavity was filled with mucinous material, and no solid implants or mucin were found in the free peritoneal cavity. The mucinous content was removed completely and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) as well as postoperative intraperitoneal chemotherapy with 5-fluorouracil (5-FU) (750 mg/m²) were performed for 5 postoperative days. Histological examination revealed disseminated peritoneal adenomucinosis according to Ronnett’s classification (fig. 2) [3]. The postoperative course was uneventful. The patient was scheduled for close follow-up and showed no relapse as well as normal levels of CEA and CA 19-9 at 24 months.

Discussion

PMP is a rare disease characterized by the spread of mucinous ascites with peritoneal and omental mucinous implants throughout the abdomen [4]. Werth was the first to describe this entity in 1884 [4]. There is a redistribution of the tumor in the abdominal cavity to predictable sites [4]. Predisposition sites are the omentum (‘omental cake’), the subhepatic region, the subdiaphragmal regions, and the ovaries. Patients usually present with an expanding abdomen (‘jelly belly’), or
PMP is diagnosed at abdominal surgery for other reasons [5–6]. PMP is mostly confined to the peritoneal cavity; however, metastases have been reported in rare cases [7–10].

The term PMP is often applied to a heterogeneous group of pathologic lesions characterized by the presence of abundant extracellular mucus with or without epithelial cells [4]. There is no uniform pathological diagnosis; peritoneal seeding from a ruptured adenoma and from a well-differentiated mucinous adenocarcinoma of the colon, most frequently the appendix, can lead to PMP. Both the appendix and the ovaries may be the origin of this disease. In most women, simultaneous occurrence in the appendix and ovaries are found [11]. A recent consensus has been reached regarding the immunohistochemical molecular genetic evidence that the appendix is the most frequent site of origin, while the ovaries are probably secondary tumor deposits [4, 12, 13].

Other origins have been described, including lung, fallopian tube, and urachus [14–16]. Ronnett et al. [3] introduced a classification system replacing the term PMP in favor of three diagnostic groups with decreasing prognosis: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis with intermediate or discordant features (PMCA-I/D), and peritoneal mucinous carcinomatosis (PMCA).

Several reports about this disease concerned the coexistence of mucinous tumors of the ovary and appendix. The causal link between ovarian and appendiceal tumors is not clear as to whether these tumors have independent origins or not. It is believed that unilateral mucinous tumors originate from the ovary and that bilateral ovarian mucinous tumors are secondary [1, 11, 17]. Ronnett et al. [11] argued that ovarian mucinous tumors with PMP mainly reflect secondary involvement. The pathogenesis of the PMP is related to perforation of the appendiceal mucocle and spreading of the mucin from the pelvis to the subdiaphragmatic area (‘redistribution phenomenon’) [18].

In some cases, synchronous mucinous tumors of the ovary and the appendix may occur and occult primary appendiceal tumors may be revealed by postoperative histopathologic examination [17]. When mucinous fluid-like materials localize in the female pelvic cavity with ovarian involvement, this may mimic ovarian carcinomatous peritonitis and may be treated as a gynecologic disease [2].

PMP occurring more than 20 years after appendectomy is infrequent, with the longest interval reported between appendectomy and diagnosis of PMP being 35 years [19, 20]. In our case, PMP first developed 10 years after appendectomy and for the second time after 5 additional years. Thus, these patients require careful observation, as PMP can possibly be detected after a long-term follow-up period of more than 20 years.

At presentation, the clinical features are diverse. Patients most frequently reported progressive abdominal distension (23–55%); a presumed diagnosis of acute appendicitis and of pelvic (ovary) mass was made in 20–27% and in 39% of the patients prior to the diagnosis of PMP, respectively, while 14% of the patients initially presented with signs and symptoms of gastrointestinal obstruction. The diagnosis of PMP was made during the evaluation of inguinal hernia (5–25%), nonspecific abdominal pain (3–9%), and occult gastrointestinal bleeding (2%, 2/97 patients) [4, 21, 22]. Though CEA and CA 19-9 concentrations have not been measured in many cases, these serum markers have occasionally been found to be elevated [1]. High serum concentrations of CEA suggest a poor prognosis and possible recurrence of the disease [23]. In the present case, the CEA level was elevated.

CT findings in PMP are diverse, including masses distributed throughout the abdomen, a thick, cystic wall or septa, scalloping of the surface of the liver, and ascites [24, 25], as well as non-specific calcification that may be seen on CT [26], similar to our case.

A Pubmed and MeSH Terms search showed only one report of two cases of localized PMP in the female pelvis [2].

Surgery is the mainstay of treatment, but the recurrence rate is high [1]. Despite the usually slow growth of this tumor, this disease is usually fatal. In recent years, efforts have been concentrated on surgery combined with adjuvant therapy. Sugarbaker [27] advocates that surgery combined with intraperitoneal chemotherapy improves survival.

Chemotherapy and radiotherapy have also been shown to be helpful [28, 29]. Some have reported the use of 5-FU, cyclophosphamide, L-phenylalanine mustard, doxorubicin, and cisplatinum [23]. The present patient received intraoperative HIPEC and postoperative intraperitoneal chemotherapy with 5-FU (750 mg/m²) for 5 days.

PMP remains a disease that follows ‘an unmitting but prolonged clinical course’ and is characterized by a high recurrence rate. Thus, Gough et al. [23] reported a recurrence rate of 76%, with half of the recurrences occurring after 2.5 years.

Prognosis of the PMP is directly related to the histological variant; survival at 5 and 10 years was 75% and 68% in the case of DPAM, 50% and 21% in the case of PMCA-I/D, and 14% and 3% in the case of PMCA, respectively [3].

Despite a much improved understanding regarding the biology of this condition, the impact of therapy is still not completely understood. Even though complete cytoreduction is associated with prolonged overall survival, disease recurrence is common and multiple operations are frequently required. Thus, these patients require careful observation, as the disease can possibly be detected after a long-term follow-up period.

Disclosure Statement

The authors declare no conflict of interest.

The trial protocol has been approved by the ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926].

The patient gave the informed consent for the data to be published.
References